Russian scientists, under the country’s Federal Medical Biological Agency (FMBA), have revealed that a novel vaccine targeting colon cancer has successfully passed preclinical trials with noteworthy results. In these animal experiments, the vaccine led to 60–80% reduction in tumor growth, while showing no significant adverse effects even after repeated administration. The development was disclosed during the 10th Eastern Economic Forum in Vladivostok, reflecting Russia’s ambition to make advances in immunotherapy.

Unlike traditional vaccines that prevent infections, cancer vaccines are designed to stimulate the body’s immune system to recognise and combat cancerous cells. This candidate is intended as a therapeutic vaccine one that helps treat the disease after onset rather than preventing cancer. While the FMBA has termed the vaccine “ready for use,” it must still undergo human clinical trials and secure regulatory approval before wide deployment.

The FMBA is also reportedly working on vaccines for glioblastoma and melanoma, with early indications of safety and efficacy. If successful, this development could mark a significant step forward for cancer immunotherapy globally but caution and rigorous testing remain essential before the hope becomes reality.